Primary Prophylaxis against Variceal Hemorrhage Pharmacotherapy vs Endoscopic Band Ligation

Similar documents
Esophageal Varices Beta-Blockers or Band Ligation. Cesar Yaghi MD Hotel-Dieu de France University Hospital Universite Saint Joseph

BETA-BLOCKERS IN CIRRHOSIS.PRO.

th Annual AISF Meeting 44 th th th, 2011 Rome, February 23 rd -26

Variceal bleeding. Mainz,

Evidence-Base Management of Esophageal and Gastric Varices

Beta-blockers in cirrhosis: Cons

Diagnostic Procedures. Measurement of Hepatic venous pressure in management of cirrhosis. Clinician s opinion

Carvedilol or Propranolol in the Management of Portal Hypertension?

ACG & AASLD Joint Clinical Guideline: Prevention and Management of Gastroesophageal Varices and Variceal Hemorrhage in Cirrhosis

Case Report: Refractory variceal bleeding Christophe Hézode, Henri Mondor Hospital, Paris-Est University, Créteil, France

Upper gastrointestinal bleeding in children. Nguyễn Diệu Vinh, MD Department of Gastroenterology

Is pharmacological therapy the best choice for primary prevention of variceal hemmorhaging in patients with hepatic cirrhosis?

NONSELECTIVE BETA-BLOCKERS IN PATIENTS WITH CIRRHOSIS: THE THERAPEUTIC WINDOW

REVIEW. Ariel W. Aday, M.D.,* Nicole E. Rich, M.D.,* Arjmand R. Mufti, M.D., and Shannan R. Tujios, M.D.

Treatment of portal hypertension in the light of the Baveno VI Consensus Conference

Invasive Evaluation of Portal Hypertension. Vincenzo La Mura, MD PhD Department of Biomedical Sciences for Health University of Milan

VARICEAL BLEEDING. Ram Subramanian MD Hepatology & Critical Care Medical Director of Liver Transplant Emory University, Atlanta.

Hemorragia por várices gastroesofágicas en la cirrosis

Beta-blocker plus nitrates for secondary prevention of variceal bleeding (Protocol)

Cost-effectiveness of hepatic venous pressure gradient measurements for prophylaxis of variceal re-bleeding Raines D L, Dupont A W, Arguedas M R

Michele Bettinelli RN CCRN Lahey Health and Medical Center

Pediatric Gastroenterology

Portal hypertension is the main complication of cirrhosis

Manejo Actual del Sangrado por Varices Gástricas

Prevention and treatment of variceal haemorrhage in 2017

Variceal bleeding is a major cause of morbidity in patients

ORIGINAL ARTICLES LIVER, PANCREAS, AND BILIARY TRACT

Prevention of the development of varices and first portal hypertensive bleeding episode

Are the benefits of beta blockers in cirrhotics only related to decreased portal hypertension?

Complication of Portal Hypertension: should the patients in the waiting list be treated differently?

A. Purpose and Scope of the Guidance PRACTICE GUIDANCE HEPATOLOGY, VOL. 65, NO. 1, 2017

The current recommended prophylaxis of variceal. Long-Term Follow-up of Hemodynamic Responders to Pharmacological Therapy After Variceal Bleeding

Luis S. Marsano, MD March 2013

Hemodynamic effect of carvedilol vs. propranolol in cirrhotic patients: Systematic review and meta-analysis

MANAGING END STAGE LIVER DISEASE IN RESOURCE LIMITED SETTINGS

CIRROSI E IPERTENSIONE PORTALE NELLA DONNA

CARLO MERKEL, MASSIMO BOLOGNESI, DAVID SACERDOTI, GIANCARLO BOMBONATO, BARBARA BELLINI, RAFFAELLA BIGHIN, AND ANGELO GATTA

Treatment of portal hypertension

GI bleeding in chronic liver disease

Index. Note: Page numbers of article titles are in boldface type.

Clinical practice guidelines on the management of variceal bleeding

Detection of Esophageal Varices Using CT and MRI

Beta-Blockers to Prevent Gastroesophageal Varices in Patients with Cirrhosis

Virtual Mentor American Medical Association Journal of Ethics December 2008, Volume 10, Number 12:

Care of the Patient With Cirrhosis

Endoscopic band ligation versus propranolol for the primary prophylaxis of variceal bleeding in cirrhotic patients with high risk esophageal varices

Comparison between Combination of Band ligation and Propranolol with Propranolol alone in Secondary Prophylaxis of Variceal bleed

Portal hypertension Guadalupe Garcia-Tsao, MD

European. Young Hepatologists Workshop. Organized by : Quantification of fibrosis and cirrhosis outcomes

Causes of Liver Disease in US

Norepinephrine versus Terlipressin for the Treatment of Hepatorenal Syndrome

The Value of Renal Artery Resistive Indices: Association with

Variceal bleeding in cirrhotic patients

Barbara Rus Gadžijev Peter Popovič Klinični inštitut za radiologijo UKC Ljubljana

Review Article Self-Expandable Metal Stents in the Treatment of Acute Esophageal Variceal Bleeding

On-Call Upper GI Bleeding. Upper Gastrointestinal Bleeding

JMSCR Vol 04 Issue 08 Page August 2016

Risk factors for 5-day bleeding after endoscopic treatments for gastroesophageal varices in liver cirrhosis

Variceal hemorrhage is a lethal complication of cirrhosis, particularly

Portal Hypertensive Gastropathy and Gastric Antral Vascular Ectasia

Management of Portal Vein Thrombosis With and Without Cirrhosis

Management of Cirrhotic Complications Uncontrolled Ascites. Siwaporn Chainuvati, MD Siriraj Hospital Mahidol University

MEDICAL PROGRESS. Review Article. N Engl J Med, Vol. 345, No. 9 August 30,

Contraindications. Indications. Complications. Currently TIPS is considered second or third line therapy for:

The role of TIPS in the management of liver transplant candidates

Management of variceal bleeding Rachael Harry, MA, MRCP, and Julia Wendon, FRCP

Controversies in Management of Portal Hypertension and Cirrhosis Complications in the Transplant Candidate

Variceal wall tension is thought to represent the key

ENCORE-PH Top-line Results

Upper Gastrointestinal Bleeding Score for Differentiating Variceal and Nonvariceal Upper Gastrointestinal Bleeding ABSTRACT

Severe carvedilol toxicity without overdose caution in cirrhosis

Practical Approach to Endoscopic Management for Bleeding Gastric Varices

Terlipressin: An Asset for Hepatologists!

Indications, results and benefits of the measurement of hepatic venous pressure gradient

A randomized study of losartan vs propranolol: Effects on hepatic and systemic hemodynamics in cirrhotic patients

Conflict of interest disclosures. Complications of end stage liver disease. None. The many complications of Cirrhosis. Portal Hypertension.

How to manage your patient with cirrhosis. HUGO E. VARGAS, M.D, FAASLD, FACG, AGAF, FACP Professor of Medicine MAYO CLINIC, ARIZONA

FALK SYMPOSIUM MAINZ

Learning Objectives. After attending this presentation, participants will be able to:

Portal Hypertension and Variceal Bleeding: An AASLD Single Topic Symposium 1

Endoscopic variceal ligation (EVL) is the standard-of-care

Management of Cirrhosis Related Complications

Original Article INTRODUCTION. pissn eissn X

Emricasan (IDN-6556) administered orally for 28 days lowers portal pressure in patients with compensated cirrhosis and severe portal hypertension

CLINICAL MANAGEMENT Loren Laine, M.D. Clinical Management Editor University of Southern California Los Angeles, California

Clinical Trials & Endpoints in NASH Cirrhosis

Title: The Baveno VI criteria for predicting esophageal varices: validation in real life practice

GR-MD-02 for Indication of NASH Cirrhosis: NASH-CX Clinical Trial Results

V ariceal haemorrhage is a major cause of mortality and

Index. Note: Page numbers of article titles are in boldface type.

Review Article Pathophysiology of Portal Hypertension and Esophageal Varices

ORIGINAL ARTICLES LIVER, PANCREAS AND BILIARY TRACT

Cost-effectiveness analysis of beta-blockers vs endoscopic surveillance in patients with cirrhosis and small varices

The Management of Ascites & Hepatorenal Syndrome. Florence Wong University of Toronto. Falk Symposium March 14, 2008

Useful Endoscopic Ultrasonography Parameters and a Predictive Model for the Recurrence of Esophageal Varices and Bleeding after Variceal Ligation

UPPER GASTROINTESTINAL BLEEDING IN LIVER CIRRHOSIS PATIENTS

Changes in the Clinical Outcomes of Variceal Bleeding in Cirrhotic Patients: A 10-Year Experience in Gangwon Province, South Korea

Cyanoacrylate Glue versus Band Ligation for Acute Gastric Variceal Hemorrhage - A randomized controlled trial at Services Hospital, Lahore

TIPS in the Management of Portal Hypertension Clinician s Opinion

Transcription:

Primary Prophylaxis against Variceal Hemorrhage Pharmacotherapy vs Endoscopic Band Ligation Siwaporn Chainuvati, MD Faculty of Medicine Siriraj Hospital

Outline Natural history of esophageal varices Which cirrhotic patient needs prophylaxis, how? Current data on roles of pharmacotherapy and endoscopic band ligation Cautions of beta-blocker use in cirrhosis

Natural History of EV Variceal hemorrhage occurs in 25-35% of cirrhotics and accounts for 70-80% of UGIB in these patients 50% of cirrhotics will have varices at the time of diagnosis

Guidelines for Screening for Esophageal Varices Gold standard: Esophagogastroduodenoscopy Diagnosis of cirrhosis Baveno IV consensus (2005) AASLD, ACG Guideline (2007)

No varices 7-8%/year Small varices Pre-Primary Prophylaxis Predictor of EV:HVPG > 10 mmhg 7-8%/year Large varices Primary Prophylaxis 5-15%/year Variceal bleeding 20% Mortality Secondary Prophylaxis Rebleeding Merli et al. J Hepatol 2003;38:266

Risk Indicators of First Bleeding from Esophageal Varices Variceal size Severity of liver disease (CPT) Presence of red signs Hepatic venous pressure gradient

Variceal Wall Tension (T) is a Major Determinant of Variceal Rupture Esophagus Wall thickness (w) Radius (r) Transmural pressure (tp) Varix Tension (T) T = tp x r w Groszmann, Gastroenterology 1984; 80:1611

? Simvastatin? ARB? VEGF-R inhibitor Pathophysiology of Portal Hypertension Vasodilator :ISMN Endoscopic therapies? VEGF-R inhibitor Antiviral Rx TIPS Β-blockers Terlipressin Somatostatin Bosch et al., Journal of Hepatology 2008

Therapy for Primary Prophylaxis Non-selective betablockers (NSBB) Endoscopic variceal ligation (EVL) Isosorbide mononitrate (ISMN) NSBB+ EVL NSBB+ ISMN Sclerotherapy Recommend Not recommend Garcia-Tsao et al. ACG guideline 2007

Non-selective Beta-blockers for Primary Prophylaxis Bleeding rate (2 yr) All varices (11 trials) Control NSBB Absolute rate difference 25% (n=600) 15% (n=590) -10% Large varices (8 trials) 30% (n=411) 14% (n=400) -16% (-24 to-8) Small varices (3 trials) 7% (n=100) 2% (n=91) -5% D Amico et al. Sem Liv Dis 1999

ISMN + Propranolol vs Propranolol alone for primary prophylaxis Free of a first variceal bleeding Survival 100 100 75 ns 75 ns % 50 25 Propranolol + ISMN Propranolol + placebo 50 25 Propranolol + ISMN Propranolol + placebo 0 1 Years 2 0 1 Years 2 García-Pagán et al., Hepatology 2003

Endoscopic variceal ligation plus propranolol vs endoscopic variceal ligation alone in primary prophylaxis of variceal bleeding Sarin et al, Am J Gastroenterol 2005;100:797-804

Primary Prophylaxis 20 mg twice a day Baveno IV consensus (2005) AASLD Guideline (2007) WCOG guideline Endoscopic band ligation q 2-4 weeks

Banding Ligation versus Beta-blockers for Primary Prevention in Esophageal Varices Cochran Review (1504 pts) Gludd LL, Krag A Cochran Database Systemic Review 2012

Esophageal Variceal Bleeding Rate Abillos et al. Clin Liver Dis 2010 HVPG response on NSBB, only 50% of patients were HVPG responder

Carvedilol for Primary Prophylaxis of Variceal Bleeding in Cirrhotic Patients with Hemodynamic non-response to Propranolol Patients (n) All (104) Propranolol responder 37 (36%) Carvedilol responder 38 (37%) Non-responder (EBL) 29 (28%) P value Follow-up, months Variceal bleeding,n(%) Hepatic decompensation 19.5 + 9.7 20.9+ 9.2 18.9+ 9.5 19.5+ 10.4 0.391 14 (13%) 4 (11%) 3 (8%) 7 (24%) 0.043 40 (38%) 14 (38%) 10 (26%) 16 (55%) 0.079 Death, n(%) 18 (17%) 5 (14%) 4 (11%) 9 (31%) 0.018 Bleeding related death, n(%) 8 (7%) 2 (5%) 1 (2%) 5 (17%) <0.01 Reiberger et al. Gut 2013

Double-Blind Randomized Controlled Trial of Simvastatin vs Placebo for Portal Hypertension in Cirrhosis + Simvastatin Albrades et al, Gastroenterology 2009

Effects of the Combined Administration of Propranolol plus Sorafenib on Portal Hypertension in Cirrhotic rats

Primary Prophylaxis Large varices Small varices with red signs or in Child-C Non-selective ß-blocker EVL q 2-4 weeks patient s preference, contraindication or intolerance to BB No follow up EGD once on BB Titrate to keep HR 55/min, avoid hypotension (MAP < 82 mmhg) Bosch et al., Journal of Hepatology 2008 Garcia-Tsao et al, Hepatology 2007